uniQure N.V. (LON:0EE0)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 558.76M |
| Revenue (ttm) | 15.64M |
| Net Income (ttm) | -168.40M |
| Shares Out | n/a |
| EPS (ttm) | -3.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 862 |
| Average Volume | 1,542 |
| Open | 14.26 |
| Previous Close | 14.16 |
| Day's Range | 13.76 - 14.26 |
| 52-Week Range | 3.75 - 19.13 |
| Beta | n/a |
| RSI | 45.20 |
| Earnings Date | Aug 8, 2025 |
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ... [Read more]
Financial Performance
In 2024, uniQure's revenue was $27.12 million, an increase of 71.17% compared to the previous year's $15.84 million. Losses were -$239.56 million, -22.34% less than in 2023.
Financial numbers in USD Financial StatementsNews
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene...
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
uniQure's AMT-130 Gene Therapy Warrants An Upgrade
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache...
uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
uniQure GAAP EPS of -$0.82 beats by $0.18, revenue of $1.57M misses by $5.14M
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related...
Earnings Outlook For uniQure
uniQure (NASDAQ: QURE) is set to give its latest quarterly earnings report on Friday, 2025-05-09. Here's what investors need to know before the announcement. Analysts estimate that uniQure will repor...
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
uniQure to Announce First Quarter 2025 Financial Results
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ ~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volat...
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
uniQure's AMT-130 shows 80% Huntington's Disease progression slowing. Click to read more on QURE's financially strong, advancing therapies for ALS & Fabry, and with FDA talks in 2025.
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday. Shares of uniQure N.V . (NASDAQ: QURE) rose sharply during Thursday's session after the company was granted FDA...
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.’s (NASDAQ: QURE) AMT-130 for Huntington’s disease on Thursday This designation is in addition to t...
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.'s QURE AMT-130 for Huntington's disease on Thursday
uniQure jumps on FDA breakthrough tag for Huntington’s disease drug
uniQure (QURE) stock surges 39% as FDA grants Breakthrough Therapy designation for AMT-130, a gene therapy for Huntington’s disease. Read more here.
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~
uniQure GAAP EPS of -$4.92 misses by $0.97, revenue of $27.1M misses by $12.3M
uniQure's FY results reported a GAAP EPS of -$4.92, missing forecasts by $0.97. Revenue grew 71.1% Y/Y to $27.1M but missed expectations by $12.3M.
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential B...
uniQure N.V.: A Potential Huntington's Play
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
According to multiple media reports on Thursday, Pfizer Inc. (NYSE: PFE) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez. In April 2024, the FDA a...
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited (OTC: CSLLY) and uniQure Inc (NASDAQ: QURE) announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgeni...
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dez...